

Diagnostic value of a combined C-reactive protein and haptoglobin test in new cases of upper tract urothelial carcinoma

Hossein Beig-Mohammadi¹, Nahid Masoudian¹, Ali Tabibi², Abdolamir Allameh^{3*}

1. Department of Biology, Faculty of Basic Science, Damghan Branch, Islamic Azad University, Damghan, Iran
2. Labbafinejed Hospital, Shaheed Beheshti University of Medical Sciences, Tehran, Iran
3. Department of Clinical Biochemistry, Faculty of Medical Sciences, Tarbiat Modares University, POB 14115-331, Tehran, Iran

***Corresponding author:** Tel: +98 2182883877 Fax: +98 218006544

Address: Department of Clinical Biochemistry, Faculty of Medical Sciences, Tarbiat Modares University, POB 14115-331, Tehran, Iran

E-mail: allameha@modares.ac.ir

Received: 2015/11/15 revised: 2016/01/9 accepted: 2016/02/19

Abstract

Introduction: Serum C-reactive protein (CRP) is believed to be increased in metastatic urothelial cancer of the bladder. However, the changes depend on the stage and grade of the upper tract urothelial carcinoma (UTUC). This study aimed to compare low-range and high-range serum CRP and haptoglobin in new cases of UTUC.

Materials and methods: Blood was collected from newly diagnosed patients with UTUC (n=43 patients; 39 male/4 female) and normal individuals (n=26; 24 male and 2 female) with no sign of infection or cancer. All the patients showed clinical symptoms of bladder cancer. Serum CRP and haptoglobin were estimated based on conventional methods.

Results: Haematuria and polyuria were common symptoms in 65.12% of the patients suffering from UTUC. The serum level of HAPT in control and UTUC patients was 126 ± 13 and 181 ± 14.5 mg/dl respectively. No significant difference was observed in HAPT level in patients and controls. The HAPT was in the high-range level in 27% of controls and 30% of the patients. The average serum CRP level in patients and controls was 11.87 ± 3.5 mg/l and 11.45 ± 4.2 mg/l, respectively. Serum CRP was above 3.5 mg/l (>3.5 mg/l) in 46% of patients (20/43). The CRP level was significantly higher ($P=0.023$) in patients having CRP above 3.5 mg/l compared to respective controls.

The UTUC patients were separated into two groups based on low-range (<3.5 mg/l) and high-range CRP (>3.5 mg/l). Serum CRP was <3.5 mg/l in 69% of the controls, whereas 31% of controls had CRP >3.5 mg/l. However, 46% of UTUC patients had serum CRP >3.5 mg/l and 54% of UTUC patients had serum CRP <3.5 mg/l.

Conclusion: Although there was no difference in haptoglobin levels in patients and controls, but serum CRP was significantly increased in patients and it was associated with clinical symptoms of UTUC, suggesting that serum CRP can be considered as a complementary test for detection of low-grade UTUC.

Keywords: Bladder cancer, Biomarkers, CRP, Haptoglobin, Low-grade

Introduction

Urothelial carcinoma is the most common malignancy which develops in epithelium of bladder, ureter and kidney. Upper urinary tract urothelial carcinoma (UTUC) and bladder cancer is arising from the

epithelial lining (i.e., the urothelium) of the urinary bladder. It is a disease in which abnormal cells multiply without control in the bladder (1, 2).

Currently, the gold standard for diagnosis of bladder cancer is to receive biopsy during cystoscopy. In this procedure a visual detection by transurethral resection of bladder tumor (TURBT) is followed by transurethral surgery. Urine cytology is also used as an important diagnosis test with high specificity but low sensitivity for low-grade bladder tumors (3). According to Lu et al., 2014, only 66.7% of UTUC patients show carcinoma cell in urine cytology (4). There are also other non-invasive urine bound markers available as aids in the distinction of bladder cancer, including human complement factor H-related protein, high-molecular-weight carcinoembryonic antigen (CEA), and nuclear matrix protein 22 (NMP22) and urinary bladder cancer antigen, CYFRA 21-1 and NMP22 (3, 5, 6). Other non-invasive urine based tests include the CertNDx Bladder Cancer Assay, which combines mutation detection in fibroblast growth factor receptor-3 (FGFR3) with protein and DNA methylation markers to detect cancers across stage and grade, UroVysion™ for detection of aneuploidy of chromosome 3,7 and 17 and loss of 9p21 locus (7-9).

Interest has been reported in identification of reliable biochemical and tumor markers for diagnosis of upper tract urothelial carcinoma of bladder. In this line very recently Lu et al., 2015 (4) used immunological and proteomic analysis in urine sample to examine the potential value of selected markers in UTUC patients. In recent years it has been reported that serum CRP level is associated with survival of patients suffering from various cancers including; localized and metastatic renal cell carcinoma, upper urinary tract and penile cancers (10, 11).

The progression of UTUC is associated with systemic inflammation, but there are controversies over the inflammatory responses for prediction of cancer development. In this line, there are controversies over the use of serum C-reactive protein (CRP) as an acute-phase reactant in diagnosis and progression of

URT. CRP is recognized as an infection and inflammatory index; however the association of CRP-related responses to UTUC malignancy requires further investigation.

The value of serum CRP in diagnosis of metastatic urothelial cancer cancers of the bladder has been investigated (12). This study suggests that the serum CRP value prior to regular treatment could be of prognostic significance in patients with metastatic urothelial cancer of the bladder. Likewise, Stein et al. (13), reported that the preoperative high levels of serum C-reactive protein (CRP) is associated with locally advanced and metastatic UUT-UC. Haptoglobin is also an acute phase protein; the main function of this plasma protein is to bind to hemoglobin produced as a result of hemolysis. There are evidences which show that haptoglobin possess antioxidant activity and can contribute to the acute phase responses.

The association of serum total haptoglobin levels with the development of different types of malignancies in humans has been investigated. An association between alpha-1-antitrypsin and haptoglobin phenotype particularly type 2-2 has been reported in bladder cancer patients (14). According to Kang et al. (15), the haptoglobin β -chain is elevated in patients suffering from lung cancer, suggesting that the haptoglobin β -chain can be used as a supportive biomarker for human lung cancers. Studies on the haptoglobin genotypes (polymorphism) in breast cancer patients in Jordan showed that the frequency of Hp1 and Hp2 allele is higher in non-familial breast cancer compared to that in familial breast cancer (15). More recently a report from Turkey by Piriñçi et al. (16), showed that serum haptoglobin levels increases in patients with bladder cancer compared to healthy controls. Moreover, it was demonstrated that the levels of haptoglobin protein increased with increasing tumor grades and were significantly higher in patients with metastatic disease and the presence of

lymphovascular involvement, lymph node metastases and increasing tumor burden. It has also been demonstrated that elevated haptoglobin levels are associated with a higher stage, grade, and measure of distant metastasis and larger tumor size, suggesting that the elevated serum haptoglobin levels may provide a useful diagnostic and treatment biomarker for patients with bladder cancer.

Despite the studies using either CRP or haptoglobin as new biomarkers for diagnosis of bladder cancer, there are two issues to be addressed in the present case-control study. Firstly, the implication of CRP and/or haptoglobin in early detection of low-grade tumors of bladder cancer. This can be achieved by measuring these parameters in patients prior to systemic therapy. Secondly, the usefulness of a combined tests (CRP and haptoglobin) for early diagnosis of bladder cancer.

Materials and methods

Patients and sample collection: This case-control study was carried out on a group of patients with UTUC symptoms and a group controls. The patients referred to the hospital with urinary complications, such as polyuria, dysuria and hematuria. As shown in Table 1, the study population consist of patients (n=43) and a control group with age-and sex match subjects (n=26) who had no acute or chronic diseases.

Blood sample was collected by venepuncture from each patient after undergoing sonography and cystoscopy. After obtaining the demographic information of each individual, blood was collected; serum was separated and stored at freezer for biochemical assays.

The study protocol conforms to the ethical guidelines of the Declaration of Helsinki as reflected in the guidelines of the Medical Ethics Committee, Ministry of Health of Iran. Blood was collected from each subject after informed consent was given.

Measurement of serum CRP: Serum CRP was measured by nephelometric method using MININEPH™ kit (The Binding Site

Group Ltd, Birmingham, UK). All the assays were carried out in duplicate and the results were presented as mean \pm SD.

Estimation of serum haptoglobin: Serum Haptoglobin was estimated by immunoturbidimetric assay using a commercially available kit; Tina-quant Haptoglobin ver.2 (Cobas Integra) purchased from Roche Diagnostics, Mannheim, Germany). In this assay human haptoglobin forms a precipitate with a specific antiserum which is determined at 340 nm.

Results

In this study levels of CRP and total haptoglobin were measured in serum samples collected from patients diagnosed with bladder cancer (UTUC) based on cystoscopy. The patients were new cases prior to medical interference. Besides serum samples from normal individuals were used as control to compare the data.

As shown in Table 1, most of the cases were male and 55.81% of patients were smoking. More than 65% of patients (28/43) suffered from hematuria. As shown, all the 43 patients (100%) underwent cystoscopy/sonography as part of diagnosis program and proved to be positive for this assay.

Table 1. Demographic information of in upper tract urothelial carcinoma patients and normal subjects.

Characteristics	Controls	Patients
Age (year)	44-88	25-86
Smoking	9(34.61%)	24(55.81%)
Hematuria	0%	28(65.12%)
Cystoscopy/Sonography	0%	43(100%)

In this study serum CRP levels was categorized into two sub-groups (CRP<3.5 Vs CRP>3.5 mg/l). Based on this, serum CRP in approximately 50% of patients was above 3.5 mg/l (>3.5 mg/l). The serum CRP levels was significantly higher (P<0.05) in patients with CRP>3.5 compared to respective controls (CRP >3.5 mg/l). However CRP levels >3.5 mg/l comprised about 30% of the control samples. Serum

CRP levels in control samples was <3.5 mg/l in about 70% (18/26) of control samples.

The samples were divided based on the haptoglobin level of less than 200mg/dl and those having haptoglobin levels above 200 mg/dl. In normal samples, 73% (19/26) of samples showed haptoglobin between 50 to 200, whereas 26.9% of the control samples showed haptoglobin levels between <50 to >200 mg/l.

In the cancer patients, about 70% of cases (30/43) showed low haptoglobin. Whereas, 30% (13/43) of cases showed high serum haptoglobin levels. The minimum level of haptoglobin in cancer patients was found to be 67.01 mg/dl, whereas in controls minimum level was 13.79. Maximum serum haptoglobin in the patients and controls was 502.17 and 297.58 mg/dl, respectively.

Discussion

Urinary biomarkers are often measured along with urine cytology for diagnosis and follow up of UTUC. However the sensitivity of these tests is low and may even be lower in low-grade tumors. There are many types of tumor markers the levels of which may be elevated and signify metastasis and recurrence of cancer of UTUC.

It has been suggested that serum-based tumor markers along with the urine cytology which is a specific test for bladder cancer can be used for low-grade tumors. There are evidences which show that inflammatory reactions which appear early before tumor formation play important role in predisposing epithelial cells to cancerous lesions and promotion of cancer. The inflammation and infectious conditions can trigger immune system and the release of immune mediators in circulation. The acute phase reactants (APRs) are released in response to such conditions. CRP and haptoglobin are among the APRs which are believed to change as a result of inflammatory responses such as cancerous lesions. However, the drawback of

inflammatory mediators as biomarkers is their low specificity to a disease such as cancer. The use of a marker such as CRP in combination with other markers has been suggested for diagnosis of cancers.

The parameters associated with inflammation can be used as complementary marker for cancer diagnosis particularly at advanced stages of tumorigenesis. Changes in serum total haptoglobin as well as its chains (alpha and beta) have been measured as patients suffering from UTUC cancer. The results of the present study clearly show that serum total haptoglobin is not significantly changes in new cases of UTUC subjects. These data may suggest that haptoglobin level remains within the normal range in new diagnosed patients and probably this marker is useful for measuring in patient with advance cancer and at metastatic stage. Haptoglobin changes may also be helpful marker if measured in terms of alpha/beta chains. Studies revealed that changes in expression of haptoglobin chains are promising for diagnosis of lung cancer (Kang *et al.*, 2001). This finding is further confirmed by the report of Park *et al.*) by showing that secretion of alpha and beta chains of haptoglobin are significantly elevated in patients diagnosed with non-small cell lung carcinoma (NSCLC). The differences in total serum haptoglobin between control and bladder patient could even be more prominent if measured by more sensitive assays such as ELISA. According to Pirincci and co-workers), ELISA technique can help distinguish increased level of serum haptoglobin in patients with bladder cancer compared to healthy controls. Moreover, using ELISA technique it was reported that the levels of haptoglobin protein increased with increasing tumor grades and were significantly higher in patients with metastatic disease and the presence of lymphovascular involvement, lymph node metastases and increasing tumor burden. Serum CRP is often measured for diagnosis of diseases associated with chronic

inflammation. In diagnostic laboratories, the serum level of CRP above 3.5 is considered abnormal for cases with inflammatory reactions. Currently, CRP is not a routine test for diagnosis of bladder cancer because there are controversies over the range of normal of serum CRP in research reports. Saito et al. (20), suggested the diagnostic value of serum CRP in terms of CRP<5 and CRP>5. However, a comparative analysis of these data showed that the detection limit of serum CRP>3.5 is reliable for discrimination between new cases of bladder cancer and normal samples.

The use of either of these tests alone or as a combined test for prediction of UTUC needs assay development considering sensitivity and specificity characteristics. It appears that these markers may be useful for distinguishing normal samples from patients at progression or metastasis stages. It is worth mentioning that development of cancer stages is associated with non-specific reactions such as inflammation and infection. Hence, the elevated factors particularly CRP could be assigned to tumor-associated responses. This finding was further attested by showing that more

than 45% of UTUC patients had serum CRP levels above 3.5 mg/l. In comparison about 70% of the control individuals had serum CRP<3.5 mg/l. Increased level of serum CRP was inconsistent with cystoscopy results and symptoms of bladder cancer.

When comparing the levels of serum total haptoglobin and CRP in terms of positive was beyond normal range in 26-30% of the samples both controls and patients. This data suggest that total serum haptoglobin has poor diagnostic value for low-grade UTUC. Nevertheless, increased serum levels of CRP above the normal range in approximately 50% of the bladder cancer patients may be promising as a biochemical diagnostic value in new cases of bladder cancer. Moreover, the kinetics of CRP release and the analysis of dynamic changes in CRP concentrations over time may be implicated in prediction of tumor aggressiveness and treatment efficacy of urological cancers (18)

In conclusion it appears that although there is no strong association between clinical signs and symptoms of UTUC and serum haptoglobin levels, serum CRP level has diagnostic potential as a complementary marker for early diagnosis of UTUC.

References

1. Li WM, Li CC, Ke HL, Wu WJ, Huang CN, Huang CH. The prognostic predictors of primary ureteral transitional cell carcinoma after radical nephroureterectomy. *J Urol.* 2009; 182(2): 451-8.
2. Oldbring J, Glifberg I, Mikulowski P, Hellsten S. Carcinoma of the renal pelvis and ureter following bladder carcinoma: frequency, risk factors and clinicopathological findings. *J Urol.* 1989; 141(6):1311-3.
3. Shariat S, Karam JA, Lotan Y, Karakiewicz PI. Critical evaluation of urinary markers for bladder cancer detection and monitoring. *Rev Urol.* 2008; 10 (2), 120-35.
4. Lu CM, Lin JJ, Huang HH, KoYC, Hsu L, Chen JC, et al. A panel of tumor markers, calreticulin, annexin A2, and annexin A3 in upper tract urothelialcarcinoma identified by proteomic and immunological analysis. *BMC Cancer.* 2014; 14(1): 363-73.
5. Washino S, Hirai M, Matsuzaki A, Kobayashi Y. Clinical usefulness of CEA, CA19-9, and CYFRA 21-1 as tumor markers for urothelial bladder carcinoma. *Urol Int.* 2011; 87(4):420-8.
6. Sanchez-Carbayo M, Urrutia M, Silva JM, Romani R, Gonzalez JM, De Buttrago JA, et al. Comparative predictive values of urinary cytology, urinary bladder cancer antigen, CYFRA 21-1 and NMP22 for evaluating

- symptomatic patients at risk for bladder cancer. *J Urol*. 2001; 165 (5):1462-7.
7. Halling KC, King W, Sokolova IA. A comparison of BTA stat, hemoglobin dipstick, telomerase and Vysis UroVysion assays for the detection of urothelial carcinoma in urine. *J Urol*. 2002; 167(5): 2001-6.
 8. Moonen PM, Merckx GF, Peelen P, Karthaus HF, Smeets DF, Witjes JA. UroVysion compared with cytology and quantitative cytology in the surveillance of non-muscle-invasive bladder cancer. *Eur Urol*. 2007; 51(5):1275-80.
 9. Bonberg N, Taeger D, Gawrych K, Johnen G, Banek S, Schwentner C, et al. Chromosomal instability and bladder cancer: the UroVysion(TM) test in the UroScreen study. *BJU Int*. 2013; 112(4):E372-82.
 10. Steffens S, Kohler A, Rudolph R, Eggers H, Seidel C, Janssen M, et al. Validation of CRP as prognostic marker for renal cell carcinoma in a large series of patients. *BMC Cancer*. 2012; 12(1):399-404.
 11. Steffens S, Al Ghazal A, Steinestel J, Lehmann R, Wegener G, Schnoeller TJ, et al. High CRP values predict poor survival in patients with penile cancer. *BMC Cancer*. 2013; 13:223-7.
 12. Eggers H, Seidel C, Schrader AJ, Lehman R, Wegener G, Kuczyk MA, et al. Serum C-reactive protein: a prognostic factor in metastatic urothelial cancer of the bladder. *Med Oncol*, 2013; 30 (4) 705-10.
 13. Stein B, Schrader AJ, Wegener G, Seidel C, Kuczyk MA, Steffens S. Preoperative serum C-reactive protein: a prognostic marker in patients with upper urinary tract urothelial carcinoma. *BMC Cancer*. 2013; 13:101.
 14. Benkman HG, Hanssen HP, Ovenbeck R, Goedde HVV. Distribution of alpha-1 antitrypsin and haptoglobin phenotypes in bladder cancer patients. *Hum Hered*, 1987; 37(5) 290-3.
 15. Kang SM, Sung HJ, Ahn JM, Park JY, Lee SY, Park CS, et al. The haptoglobin beta-chain as a supportive biomarker for human lung cancers. *Mol Biosys*. 2011; 7(4) 1167-75.
 16. Awadallah SM, Atoum MF. Haptoglobin polymorphism in breast cancer patients from Jordan. *Clin Chim Acta*, 2004; 341(1-2) 17-21.
 17. Pirincci N, Gecit I, Gunes M, Kemik AS, Yuksel MB, Kaba M, et al. Haptoglobin levels in Turkish patients with bladder cancer and its association with clinicopathological features. *Asian Pac J Cancer Prev*. 2012;13(12):6063-6.
 18. Saito K, Kihara K. C-reactive protein as a biomarker for urological cancers. *Nat Rev Urol*. 2011; 8(12):659-66.